Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
Prossomariti A, Scaioli E, Piazzi G, Fazio C, Bellanova M, Biagi E, Candela M, Brigidi P, Consolandi C, Balbi T, Chieco P, Munarini A, Pariali M, Minguzzi M, Bazzoli F, Belluzzi A, Ricciardiello L
Scientific reports · 55 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo clínico controlado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Posiblemente financiado por la industria
- Autores
- Al menos un autor declara un vínculo económico con la industria
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2017-08-01 · Sci Rep · vol. 7 · número 1 · pág. 7458
- Editorial
- Nature Portfolio
- Citado
- 68 citas · más que el 92% de estudios similares · 3.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 61 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- IL-33, ST2, and ILC Pathways · Cancer-related molecular mechanisms research · Helicobacter pylori-related gastroenterology studies
- Palabras clave
- Gastroenterology, Eicosapentaenoic acid, Ulcerative colitis, Calprotectin, Internal medicine, Medicine, Inflammation, Gut flora, Colitis, Inflammatory bowel disease, Feces, Fatty acid, Immunology, Disease, Biology, Microbiology, Biochemistry, Polyunsaturated fatty acid
- MeSH
- humans, colitis, ulcerative, eicosapentaenoic acid, fatty acids, nonesterified, leukocyte l1 antigen complex, interleukin-10, treatment outcome, pilot projects, gene expression regulation, phosphorylation, adult, aged, aged, 80 and over, middle aged, female, male, stat3 transcription factor, kruppel-like transcription factors, young adult, microbiota, transcription factor hes-1, suppressor of cytokine signaling 3 protein, kruppel-like factor 4
17 autores
- Anna Prossomariti🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Eleonora Scaioli🇮🇹University of Bologna
- Giulia Piazzi🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Chiara Di Fazio🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Matteo Bellanova🇮🇹University of Bologna
- Elena Biagi🇮🇹University of Bologna
- Marco Candela🇮🇹University of Bologna
- Patrizia Brigidi🇮🇹University of Bologna
- Clarissa Consolandi🇮🇹Institute of Biomedical Technologies; National Research Council
- Tiziana Balbi🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
- Pasquale Chieco🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Alessandra Munarini🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Milena Pariali🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Manuela Minguzzi🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola; University of Bologna
- Franco Bazzoli🇮🇹University of Bologna
- Andrea Belluzzi🇮🇹IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
- Luigi Ricciardiello🇮🇹 · autor de correspondenciaUniversity of Bologna
Resumen
El texto original del estudio, en el idioma en que se publicó.
Patients with long-standing ulcerative colitis (UC) have an increased colorectal cancer (CRC) risk. In this pilot study we evaluated the effect of Eicosapentaenoic acid as free fatty acid (EPA-FFA) supplementation on mucosal disease activity, colonic differentiation markers and microbiota composition in UC patients. Twenty long-standing UC patients in stable clinical remission and with fecal calprotectin (FC) > 150 µg/g were enrolled (T0) and supplemented with EPA-FFA 2 g/daily for 90 days (T3). Endoscopic and histologic disease activities were measured by Mayo and Geboes scores, respectively. HES1, KLF4, STAT3, IL-10 and SOCS3 levels were determined using western blotting and qRT-PCR, while phospho-STAT3 levels were assessed by western blotting. Goblet cells were stained by Alcian blue. Microbiota analyses were performed on both fecal and colonic samples. Nineteen patients completed the study; seventeen (89.5%) were compliant. EPA-FFA treatment reduced FC levels at T3. Patients with FC > 150 µg/g at T3 (n = 2) were assumed as non-responders. EPA-FFA improved endoscopic and histological inflammation and induced IL-10, SOCS3, HES1 and KLF4 in compliant and responder patients. Importantly, long-term UC-driven microbiota composition was partially redressed by EPA-FFA. In conclusion, EPA-FFA supplementation reduced mucosal inflammation, promoted goblet cells differentiation and modulated intestinal microbiota composition in long-standing UC patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.